AR086818A1 - Forma cristalina b de la 2,2,2-trifluoro-n-[(1r,2s)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamida - Google Patents
Forma cristalina b de la 2,2,2-trifluoro-n-[(1r,2s)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamidaInfo
- Publication number
- AR086818A1 AR086818A1 ARP120102359A ARP120102359A AR086818A1 AR 086818 A1 AR086818 A1 AR 086818A1 AR P120102359 A ARP120102359 A AR P120102359A AR P120102359 A ARP120102359 A AR P120102359A AR 086818 A1 AR086818 A1 AR 086818A1
- Authority
- AR
- Argentina
- Prior art keywords
- indazol
- propan
- trifluoro
- acetamide
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formas cristalinas de 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamida, procesos para obtenerlas, intermedios farmacéuticos empleados en su elaboración, composiciones farmacéuticas que las contienen y su uso en tratamientos médicos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161502656P | 2011-06-29 | 2011-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086818A1 true AR086818A1 (es) | 2014-01-22 |
Family
ID=46420454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120102359A AR086818A1 (es) | 2011-06-29 | 2012-06-29 | Forma cristalina b de la 2,2,2-trifluoro-n-[(1r,2s)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamida |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP2726464A1 (es) |
JP (1) | JP2014527955A (es) |
KR (1) | KR20140036230A (es) |
CN (1) | CN103814015A (es) |
AR (1) | AR086818A1 (es) |
AU (1) | AU2012277514A1 (es) |
BR (1) | BR112013031759A2 (es) |
CA (1) | CA2839398A1 (es) |
IN (1) | IN2014MN00023A (es) |
MX (1) | MX2013014566A (es) |
RU (1) | RU2013153466A (es) |
SG (1) | SG195309A1 (es) |
TW (1) | TW201305115A (es) |
UY (1) | UY34170A (es) |
WO (1) | WO2013001294A1 (es) |
ZA (1) | ZA201309480B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017161518A1 (en) | 2016-03-23 | 2017-09-28 | Astrazeneca Ab | New physical form |
CN108314670B (zh) * | 2018-02-06 | 2020-04-07 | 江苏八巨药业有限公司 | 一种(s)-2-氯-1-(6-氟-1-苯并二氢吡喃-2-基)-乙醇的制备方法 |
KR20230113770A9 (ko) * | 2020-11-27 | 2024-03-25 | 미라이랩 바이오사이언스 인코퍼레이티드 | 고순도 β 니코틴아미드 모노뉴클레오티드(NMN) 및 그 제조 방법 |
KR102571432B1 (ko) * | 2023-02-08 | 2023-08-29 | 주식회사 에스씨엘테라퓨틱스 | 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
SE9101090D0 (sv) | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
GB0315509D0 (en) | 2003-07-02 | 2003-08-06 | Meridica Ltd | Dispensing device |
JO2754B1 (en) | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
WO2008079073A1 (en) | 2006-12-22 | 2008-07-03 | Astrazeneca Ab | Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders |
IN2013MN00222A (es) | 2010-07-21 | 2015-05-29 | Astrazeneca Ab | |
MX2013000687A (es) | 2010-07-21 | 2013-01-29 | Astrazeneca Ab | Inhalador. |
-
2012
- 2012-06-27 WO PCT/GB2012/051503 patent/WO2013001294A1/en active Application Filing
- 2012-06-27 SG SG2013089966A patent/SG195309A1/en unknown
- 2012-06-27 IN IN23MUN2014 patent/IN2014MN00023A/en unknown
- 2012-06-27 RU RU2013153466/04A patent/RU2013153466A/ru not_active Application Discontinuation
- 2012-06-27 CA CA2839398A patent/CA2839398A1/en not_active Abandoned
- 2012-06-27 BR BR112013031759A patent/BR112013031759A2/pt not_active IP Right Cessation
- 2012-06-27 JP JP2014517935A patent/JP2014527955A/ja active Pending
- 2012-06-27 CN CN201280039142.8A patent/CN103814015A/zh active Pending
- 2012-06-27 KR KR1020137033086A patent/KR20140036230A/ko not_active Application Discontinuation
- 2012-06-27 MX MX2013014566A patent/MX2013014566A/es not_active Application Discontinuation
- 2012-06-27 AU AU2012277514A patent/AU2012277514A1/en not_active Abandoned
- 2012-06-27 EP EP12731150.4A patent/EP2726464A1/en not_active Withdrawn
- 2012-06-28 TW TW101123228A patent/TW201305115A/zh unknown
- 2012-06-28 UY UY0001034170A patent/UY34170A/es not_active Application Discontinuation
- 2012-06-29 AR ARP120102359A patent/AR086818A1/es unknown
-
2013
- 2013-12-13 ZA ZA2013/09480A patent/ZA201309480B/en unknown
Also Published As
Publication number | Publication date |
---|---|
UY34170A (es) | 2013-01-31 |
ZA201309480B (en) | 2015-10-28 |
IN2014MN00023A (es) | 2015-06-12 |
RU2013153466A (ru) | 2015-08-10 |
CN103814015A (zh) | 2014-05-21 |
EP2726464A1 (en) | 2014-05-07 |
WO2013001294A1 (en) | 2013-01-03 |
AU2012277514A1 (en) | 2014-01-09 |
CA2839398A1 (en) | 2013-01-03 |
KR20140036230A (ko) | 2014-03-25 |
SG195309A1 (en) | 2013-12-30 |
BR112013031759A2 (pt) | 2016-12-13 |
JP2014527955A (ja) | 2014-10-23 |
TW201305115A (zh) | 2013-02-01 |
MX2013014566A (es) | 2014-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015003801A1 (es) | Formulaciones de anticuerpos y metodos | |
NI201400070A (es) | Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido. | |
CL2013003227A1 (es) | “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct | |
CL2016001120A1 (es) | Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct | |
GT201400147A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
UY35492A (es) | Compuestos novedosos | |
AR084691A1 (es) | Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel | |
CL2009001066A1 (es) | Compuestos derivados del acido ciclopentano carboxilico sustituido; inhibidores del receptor lpa edg2; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, metabolicas, renales, pulmonares, oncologicas, inmunologicas y alergias, entre otras. | |
ECSP13012770A (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina | |
DOP2014000133A (es) | Triazolopiridinas sustituidas | |
ECSP10010489A (es) | Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparación | |
UY33370A (es) | Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización | |
UY32427A (es) | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma | |
CR20130033A (es) | Formulaciones de rifaximina y usos de las mismas | |
ECSP13012368A (es) | Composiciones farmacéuticas de co-cristales de tramadol y coxibs | |
CR20160222U (es) | Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas | |
DOP2016000253A (es) | Nuevos compuestos | |
ECSP13013011A (es) | Triazolopiridinas | |
CL2009001484A1 (es) | Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia. | |
CR20140175A (es) | Compuestos y métodos para mejorar las respuestas inmunitarias innatas | |
UY32464A (es) | Nuevos compuestos de indazol | |
UY32052A (es) | 5-aminopirazoles sustituidos y uso de los mismos | |
PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
CL2012000097A1 (es) | Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros. | |
AR086818A1 (es) | Forma cristalina b de la 2,2,2-trifluoro-n-[(1r,2s)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |